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User considerations in assessing pharmacogenomic tests and
their clinical support tools
Gouri Mukerjee1, Andrea Huston1, Boyko Kabakchiev1,2, Micheline Piquette-Miller3, Ron van Schaik4 and Ruslan Dorfman1
Pharmacogenomic (PGx) testing is gaining recognition from physicians, pharmacists and patients as a tool for evidence-based
medication management. However, seemingly similar PGx testing panels (and PGx-based decision support tools) can diverge in
their technological speciﬁcations, as well as the genetic factors that determine test speciﬁcity and sensitivity, and hence offer
different values for users. Reluctance to embrace PGx testing is often the result of unfamiliarity with PGx technology, a lack of
knowledge about the availability of curated guidelines/evidence for drug dosing recommendations, and an absence of wide-spread
institutional implementation efforts and educational support. Demystifying an often confusing and variable PGx marketplace can
lead to greater acceptance of PGx as a standard-of-care practice that improves drug outcomes and provides a lifetime value for
patients. Here, we highlight the key underlying factors of a PGx test that should be considered, and discuss the current progress of
PGx implementation.
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INTRODUCTION
Pharmacogenomics (PGx) is the study of inherited genetic
information that inﬂuences drug response and determines drug
behavior. This inherently personalized approach to medicine can
improve drug efﬁcacy and has the potential to engage patients in
their own health care, leading to better treatment adherence and
outcomes. Implementation projects using PGx-guidance for drug
therapy have demonstrated a high frequency of pharmacogen-
etically relevant genomic variants in the general population and a
potential value of PGx-guided drug selection.1,2 Research pro-
grams in PGx implementation are underway in Canada (Go-PGx,
IMPACT), EU (U-PGx), and US (eMERGE) and publications reviewing
clinical applications of PGx have summarized challenges and
provided recommendations for moving forward.3,4
The use of PGx as a tool for evidence-based medication
management is gaining acceptance beyond academic medical
centers and hospital systems with many users—individuals, health
professionals, and health plans—expressing an interest in using
PGx tests to predict efﬁcacy and side effects of drugs. In addition
to PGx tests used in medical centers and hospital settings, there
are numerous commercially available PGx-based decision support
tools (DSTs) on the market utilizing different genetic panels
(Supplementary Table 1) with dissimilar medication coverage.
Bousman and Dunlop examined the degree of agreement in
medication recommendations between four commercial PGx-
based DSTs with published data in context of major depressive
disorder (MDD).5 Despite concordance in many results, a level of
disagreement in medication recommendation was observed for
antidepressants, anxiolytics/hypnotics, and antipsychotics. There-
fore, tests cannot be assumed to be equivalent or interchangeable
and users need to evaluate available tests before making a choice.
Due to limited familiarity with the technology, users often face a
challenge in comparative evaluation of available tests. Here, we
explain the different features of a PGx service, such that users can
make informed decisions to identify a test that ﬁts their needs.
PHARMACOGENOMIC TESTS
Two approaches to PGx testing have been adopted: reactive
testing and pre-emptive testing. In reactive testing, genetic tests
are ordered on an ‘as needed’ basis. If the results are deemed to
be of interest: the patient is likely to need, or has side effects from
a high-risk drug with PGx recommendations. In pre-emptive
testing, drug response genes are tested in anticipation of future
prescription events, providing a lifetime value for the test. Results
for high-risk drugs with PGx recommendations can be made
available prior to prescribing decision, consistent with the vision
that in every prescribing decision, an individual’s genomic
variation will be considered an inherent patient characteristic as
are age, weight, renal function, and allergy status.4
Pharmacogenes impact drug response
Drug response is highly variable and some of this variation is due
to inherited genetic variants. Genetic variants are estimated to
affect between 20–95% of response variability depending on the
drug.6 Variants inﬂuencing drug response are predominantly
located in genes encoding drug-metabolizing enzymes and
transporters (the ADME genes), drug targets, or human leukocyte
antigen alleles. Variations can occur in regulatory regions of the
gene affecting level of expression, as well as in the coding region
affecting the function of the gene, causing high or low exposure
to the drug, increased formation of toxic metabolites, increased/
decreased interactions with drug targets, or activation of the
immune system leading to idiosyncratic drug toxicity.
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There are many examples of PGx variants impacting drug
efﬁcacy and safety.7 Ultrarapid metabolizers of CYP2D6 can suffer
from life threatening respiratory depression when prescribed
codeine; poor metabolizers of CYP2C19 have impaired ability to
activate clopidogrel, reducing the medications’ therapeutic
efﬁcacy, and HLA variants help prescribers prevent hypersensitiv-
ity reactions to abacavir, carbamazepine, and allopurinol. Clinical
trials, regarded as the gold-standard for assessing clinical utility,
have been conducted for PGx variants associated with warfarin,8–
10 abacavir,11 statins,12 and clopidogrel.13 Validation studies are
needed to assess clinical impact and utility of other drug–gene
interactions reported.
Curated databases with PGx recommendations
Curated databases, such as the Clinical Pharmacogenetics
Implementation Consortium (CPIC), the Dutch Pharmacogenetics
Working Group (DPWG), the Pharmacogenomics Knowledge Base
(PharmGKB), and the Canadian Pharmacogenomics Network for
Drug Safety (CPNDS) are important sources of information on PGx
variants that affect drug response and prescribing guidelines
associated with these variants. Both CPIC and DPWG provide
therapeutic recommendations for more than 40 well-known gene-
drug pairs,14 while the CPNDS clinical recommendation group has
published dosing guidelines for adult and pediatric patients for a
few select drugs.
PGx assays impact sensitivity and speciﬁcity of tests
Various technologies assess pharmacogenes and selection of the
appropriate assay depends on the target population, prior
characterization of genetic variants, automation requirements,
and cost.
Targeted genotyping assays probe for preselected variants with
well-deﬁned drug-gene interactions. 'Ready-made' commercial
genotyping assays are often multiplexed PCR-based technologies
using TaqMan® hydrolysis probe chemistry (QuantStudio) or
Illumina VeraCode® ADME Core Panel. Other examples include:
bead-based immunoassay testing (Luminex), microarrays (Affyme-
trix), and MassArrays (Sequenom iPLEX® ADME Pharmacogenetic
Panel).
Targeted genotyping assays offer robust interpretation well
suited for automation of PGx reporting. The assays typically
include well-studied pharmacokinetic and pharmacodynamic
markers of the drug metabolizing enzymes (i.e., CYP2D6, CYP2C19,
CYP3A5, DPYD, TPMT, and UGT1A1), selected drug transporters
(SLCO1B1), receptors (VKORC1), and other genes associated with
drug response.
One caveat of targeted genotyping is that some assays may
include only variants common in speciﬁc ethnic populations
(usually Caucasian), thus missing other ethnicity-speciﬁc alleles.
Based on the population under investigation, the sensitivity and
speciﬁcity of a PGx genotyping assay can vary, depending on the
genetic variants included. For example, two reduced function
variant alleles important for response to the anticoagulant
warfarin (CYP2C9*2 and CYP2C9*3), are common in Caucasians
but not African-Americans. Lack of inclusion of reduced function
alleles common to African-Americans (CYP2C9*5, *6, *8, *11)
undermined early warfarin PGx clinical trials.8 Subsequent warfarin
trials in the US accounted for ethnicity-speciﬁc CYP2C9 and CYP4F2
alleles, improving prediction of warfarin maintenance dose10
(Fig. 1).
PGx sequencing assays utilizing whole-exome sequencing
(WES) and whole-genome sequencing (WGS) technologies are
variant agnostic and all genetic variants are identiﬁed. Never-
theless, sequencing has not been widely implemented due to: (i)
higher cost, (ii) the absence of functional characterization for
many less common variants, and (iii) challenges in the resolution
of copy number variations and long repeat elements. For
example, exome sequencing data for 12 pharmacogenes of the
cytochrome gene family identiﬁed multiple rare variations of
potential signiﬁcance, however, most lacked functional charac-
terization, posing a challenge on how to act on these ﬁndings.15
Also, it should be recognized that WES may not cover some
variants with well-deﬁned PGx recommendations (e.g., rs9934438
of VKORC1).
For pharmacogenes such as G6PD, sequencing technologies
offer the most effective solution. G6PD deﬁciency affects an
estimated 4.9% of the world’s population. Hundreds of genetic
variants of G6PD have been described, with wide ranging effects
on enzyme activity. Designing a genotyping assay encompassing
all functional G6PD gene variants is challenging and sequencing
stands as the most sensitive solution.
Several PGx panels with a common core of pharmacokinetic
variants in CYP2C19 and CYP2D6, as well as unique combinations
of other variants have been developed to guide prescription of
antidepressants, antipsychotics, and antianxiety drugs. Rando-
mized clinical trials utilizing these psychiatric PGx tests show PGx-
guided therapy improved tolerability and safety of treatment.16–18
Of note, psychiatric PGx tests include different combinations of
variants (Supplementary Table 1), each with a limited effect size.
A study examining the degree of agreement in medication
recommendations between four commercial PGx-based DSTs for
patients with MDD observed a level of disagreement in
recommendations.5 Agreement was highest for mood stabilizers
(84%), while it was 55–56% for antidepressants, anxiolytics/
hypnotics, and antipsychotics. The authors were unable to
determine, in most cases, the cause of inter-DST disagreements
on recommendations due to the unknown quality of the evidence
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Fig. 1 Occurrence of minor alleles as per ethnicity in the University of Alabama warfarin clinical trial shown by percentage of participants
possessing minor alleles10
User considerations in assessing pharmacogenomic tests and their. . .
G Mukerjee et al.
2
npj Genomic Medicine (2018)  26 Published in partnership with the Center of Excellence in Genomic Medicine Research
1
2
3
4
5
6
7
8
9
0
()
:,;
base used to formulate the proprietary algorithms, but hypothe-
sized the disagreement was a result of differences in the genes/
variants tested, phenotyping strategies, and algorithms used to
predict drug–gene interactions. A systematic literature review
examining CYP2D6, CYP2C19, CYP2C9, CYP1A2, CYP3A4, HTR2C,
HTR2A, and SLC6A4 found the strongest gene-outcome associa-
tions for psychiatric pharmacotherapy with CYP2D6 and
CYP2C19,19 which was endorsed by a recent study examining
treatment outcome in psychiatric care with only CYP2D6 and
CYP2C19 genetic information.20 Variants with individually small
effects may be combined into a sufﬁciently predictive test to
guide drug treatment. However, large-scale studies are needed to
replicate/validate these tests and model the combinatorial effects
of multiple variants.21
A bias towards including ‘historic’ variants appears in many
psychiatric PGx tests. Meta-analysis studies demonstrated an
association between depression and response to antidepressants
and the long/short forms (known as L/S alleles) of promoter
repeats in the SLC6A4 gene (also known as 5-HTTLPR, 5-HTT, or
serotonin transporter, SERT).22,23 Studies have identiﬁed missense
variants in the coding region of SLC6A4 and intronic SNPs that
affect response to SSRIs and SSRI-induced side effects.24,25
However, the relative effect size of each variant remains unknown.
Consequently, most psychiatric PGx tests focus on the promoter
variations (L/S alleles), while the missense variants in the coding
region of SLC6A4are not included. This is best illustrated by the
SLC6A4 rs25331 variant, as medication recommendation concor-
dance between different DSTs for patients with MDD was found to
be partly dependent on whether a PGx test included this variant.5
Modeling combinatorial effects across multiple genes is also
challenged by differences in ethnicity and clinical characteristics of
the patient cohorts used to validate PGx tests. Regardless, PGx
testing can help assess risk of side effects and efﬁcacy related to
antidepressant use.26
HAPLOTYPE DETERMINATION
Variability in drug response can be caused by a single SNP variant
or a combination of SNPs (i.e., haplotype) (Fig. 2). The alleles of
important drug metabolizing genes, such as CYP2B6, CYP2C9,
CYP2C19, and CYP2D6, are deﬁned by haplotypes. The more
variants measured within a haplotype, the greater the accuracy of
allele determination. CYP2D6 haplotypes are often deﬁned by
multiple SNPs. For example, the CYP2D6*64 allele is characterized
by 100C>T, as well as 1023C>T and 2850C>T, which are also
associated with CYP2D6*17.27
Ideally, for haplotype assignment, maternal and paternal
sequences are read independently. This distinction between
maternal and paternal derived haplotypes is known as phase.
Depending on the allele, phase can be important (Supplementary
Fig. 1).
Computational phasing
Short reads and genotyping data are often unable to resolve
maternal and paternal haplotype information. Therefore, deter-
mining phase requires additional computational interpretation.
This process is known as phasing.
Phasing genotyping or sequencing data is achieved computa-
tionally through bioinformatics algorithms that rely on statistical
inference. A few well-known algorithms have been designed to
complete this task, such as FastPHASE,28 SHAPE-IT,29 BEAGLE,30
MACH,31 and IMPUTE2.32
Indistinguishable haplotypes
Phasing complex haplotypes can be challenging due to the
inability to computationally distinguish between a haplotype pair
contained in the corresponding diplotype. For instance, the two
alleles *1 and *4 of CYP2D6 would be indistinguishable as a
diplotype from *4M and *10 based on genotyping data and most
sequencing data. This could lead to misinterpretation as *1/*4 has
an activity score of 1, while *4M/*10 has an activity score of
0.25–0.5.33 (The activity score system is used to assign functional
status to alleles, i.e., a value of 0.5 corresponds to decreased
function). One solution is to design genotyping assays that avoid
indistinguishable diplotypes by carefully selecting variants.
Commercial PGx assays often do not tend to be optimized in
this fashion.
The most complete solution to haplotype-related issues is to
utilize technologies that are based on long reads, sufﬁcient to
span the distance between markers of interest. Although fourth
generation sequencing technologies are available, such as
nanopore, they are not currently in wide use due to cost
restrictions and error rates.
COPY NUMBER VARIANT (CNV) DETERMINATION
Copy number variants (CNVs) occur when there are fewer or more
than two functional copies of genes. CNVs in pharmacogenes like
CYP2D6 impact the activity of the enzyme and as a result, the
efﬁcacy and toxicity of their substrates. Since CYP2D6 metabolizes
over 25% of currently prescribed drugs, establishing the copy
number status and speciﬁc alleles duplicated for CYP2D6 is critical
for PGx testing.
Various technologies can detect CNVs: high-density SNP
genotyping platforms, multiplex RT-PCR, next-generation sequen-
cing. All these technologies, however, have limitations.
Next generation sequencing allows for inspection of ratios
between reference and alternative allele reads to deduce allele
copy numbers at positions of interest. However, accurate CNV
determination typically requires a high depth of coverage which
increases cost. Read length and fragment length affect accuracy of
CNV determination with paired-end sequencing being more
accurate than single-end sequencing. Interpretation of WGS data
requires signiﬁcant bioinformatic resources, while algorithms for
CNV determination from whole-exome (WES) data are not fully
developed with no current established standard. Fortunately,
algorithms are constantly being developed and improved,
EXCAVATOR2 and ExCNVSS are two notable examples.
Genotyping assays using the MassARRAY® system (Agena
Bioscience, San Diego, CA, USA) or QuantStudio™ (Applied
Biosystems™) can detect CYP2D6 copy number using integrated
estimates from other copy number assays and informative
polymorphisms between CYP2D6 and CYP2D8. Although assays
Fig. 2 The number of haplotypes versus the number of variants for
common PGx genes as curated by PharmGKB. Not all haplotypes
follow the “one variant per haplotype” rule, with notable examples
being CYP2D6 and NAT2
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of smaller batches can sometimes result in inconclusive CNV
determination, inclusion of control samples of known CYP2D6
gene copy status can resolve the issue. Furthermore, development
of algorithms independent of the software provided by equip-
ment manufacturers have been found to increase the accuracy of
CNV determination for smaller sample batches.
FUNCTIONAL INTERPRETATION; TRANSLATING PGX RESULTS
INTO CLINICAL ACTION
Standardization of variant function and phenotype is a crucial step
towards the implementation of PGx. The CPIC has proposed
standardized terms to improve the understanding and interpreta-
tion of pharmacogenetic test reporting and reduce confusion by
maintaining consistent nomenclature.6 Functional annotations for
pharmacogenes are available at CPIC (https://cpicpgx.org/),
PharmGKB (https://www.pharmgkb.org/), DPWG (https://www.
pharmgkb.org/page/dpwg), and the Pharmacogene Variation
Consortium34 (https://www.pharmvar.org/).
Activity scores assign phenotype; occasional divergence
To facilitate translation of genotype into phenotype, the Activity
Score system (AS) developed by Gaedigk et al.35 for CYP2D6 is
widely accepted. It has been adopted by CPIC for most drug/gene
pair recommendations with the activity score determining the
functional classiﬁcation/phenotype to facilitate clinical use. The
published consensus terms describing allele functional status and
inferred phenotype are listed in Tables 1 and 2.36
However, the classiﬁcation of cytochrome enzymes into just
three or four categories (poor metabolizer, intermediate meta-
bolizer, normal/extensive metabolizer, and ultrarapid metabolizer)
can pose challenges, especially in the translation of highly
complex CYP2D6 genotype data into a patient’s phenotype to
guide drug therapy.35 Some genotypes may fall somewhere in-
between the categories mentioned above, leading to discrepan-
cies in functional interpretation by different groups. CPIC and
DPWG differ in their translation of genotype to phenotype for
some alleles in CYP2D6, CYP2C9, CYP2C19, and DPYD.14 For
example, DPWG assigns CYP2D6*1/*5 into the intermediate
metabolizer category, while CPIC classiﬁes CYP2D6*1/*5 as normal
metabolizer.
Creating additional functional categories can potentially
improve resolution of PGx drug dosing. In July 2016, CPIC
introduced the additional phenotype, ‘rapid metabolizer’ to
distinguish between individuals with a CYP2C19 *1/*17 (rapid
metabolizer) and CYP2C19 *17/*17 (ultrarapid metabolizer). This
new phenotype provides therapeutic recommendations on the
gene-drug interaction of CYP2C19 and voriconazole.37 Such
expansion is justiﬁed if new categories help delineate differences
or altered pharmacokinetics of a probe drug.
Exceptionally rare coding variants that have not been function-
ally characterized can also pose a challenge in functional
interpretation. While currently there is no consensus on how to
handle uncharacterized alleles, these should be ﬂagged and
reported as ‘unknown functional consequence’ to alert health-care
providers and defer clinical interpretation to PGx experts.
Guidelines; occasional discordance in recommendations
PharmGKB annotates PGx-based drug dosing guidelines published
by CPIC, DPWG, CPNDS and other professional societies, while the
FDA provides a list of drugs that contain information on PGx
biomarkers in drug labels.
A recent publication comparing therapeutic recommendations
for well-known gene-drug pair by CPIC and DPWG found
substantial agreement between recommendations by the two
consortia.14 However, differences in therapeutic recommendations
were noted for one or more aberrant phenotypes in 13 gene-drug
pairs (see Bank et al.14 for a detailed list of discordant guidelines).
Some differences were due to variance in clinical practices
between countries. Others were due to the ‘time effect’, literature
searches being performed at different time points by the two
consortia while new articles are published continuously, under-
scoring the need to continually update existing recommendations.
Guidelines can differ slightly between CPIC, DPWG, and the US
FDA’s ‘black box warning’. Guidelines for clopidogrel, an
antiplatelet agent, by CPIC and the DPWG recommend alternative
antiplatelet therapy for intermediate and poor metabolizers of
CYP2C19. In contrast, the FDA’s ‘black box warning’ on clopido-
grel, the strictest warning in labeling of prescription drugs
designed to call attention to serious or life-threatening risks,
states a danger for lower effectiveness only in CYP2C19 poor
metabolizers.
Prescribers can be made aware of PGx-related information, even
if speciﬁc dosing recommendations are not available. The FDA
labels biomarker information for carisoprodol, a muscle relaxant,
as ‘Actionable PGx’, as patients with reduced CYP2C19 activity
may have a fourfold increase in exposure to carisoprodol with a
concomitant 50% decreased exposure to meprobamate (a
metabolite of carisoprodol) compared to normal CYP2C19
metabolizers. Prescribers can use such drug label information, if
compiled into a single PGx report, to make informed decisions.
PGx reports should include references to the sources used for
guidelines, such that prescribers can weigh the strength of
evidence available.
Table 1. Activity score determination for CYP2D6 drug metabolizing enzyme
Allele functional status Example allele Allele activity score
Normal function CYP2D6*1 1
Decreased function CYP2D6*9 0.5
No function CYP2D6*4 0
Phenotype Diplotype combination Diplotype activity score
Ultra-rapid metabolizer Two normal function alleles+ gene duplication >2
Normal metabolizer Two normal function alleles 2
One normal function+ one decreased function alleles 1.5
One normal function+ one loss of function alleles 1
Two decreased function alleles 1
Intermediate metabolizer one loss of function+ one decreased function alleles 0.5
Poor metabolizer Two loss of function alleles 0
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CLINICAL IMPLEMENTATION
To implement PGx into clinical practice, timely sharing of
information and educational support must be made available to
health-care providers. PGx implementation requires digital storage
and secure, prompt accessibility of information to authorized
users, often with PGx data embedded as part of an electronic
health record (EHR) system. Early adopters of PGx programs
developed their own implementation strategies and clinical
decision support (CDS) systems. CDS systems are used to provide
patient-speciﬁc PGx recommendations, and can be integrated into
EHR. However, usability evaluations indicate that multi-
institutional efforts are warranted to develop relevant
guidelines.38
Worldwide, many PGx groups are sharing resources to further
develop implementation guidelines. The European Pharmacoge-
netics Implementation Consortium (http://www.eu-pic.net/) has
undertaken efforts to facilitate PGx implementation in clinical
practice, as well as the Royal Dutch Association for the
Advancement of Pharmacy. The National Institutes of Health’s
Pharmacogenomics Research Network, and associated eMERGE
and IGNITE networks, have initiated several PGx implementation
programs across different US sites and are studying outcomes to
develop a consensus strategy. St. Jude Children’s Research
Hospital (PG4KDS protocol) and the University of Chicago (The
1200 Patients Project) are developing model systems for the
clinical implementation of preemptive PGx.
Many commercially available PGx-based DSTs make test results
available in a portable document format (pdf). The secure transfer
of PGx test results and structured patient-speciﬁc dosing
recommendations to prescribers for both current and future use
is needed for the lifetime value of PGx tests to be realized. Some
health-care providers have developed PGx alerts for EMRs, while
others use web-based applications.
Strategies for PGx implementation
A consensus strategy to aid PGx implementation into clinical care
has emerged from the National Institutes of Health-funded IGNITE
(Implementing GeNomics In pracTicE) network.39,40 Three different
IGNITE institutions (Indiana University, University of Florida, and
Vanderbilt University) implemented PGx in real-world clinical
settings using data warehousing techniques to adapt and tailor
innovations to various contexts, with sites extracting data from
multiple sources to integrate clinical records across organizations
into a central repository (Table 3).
Indiana University conducted PGx testing for 24 widely used
drugs in a hospital setting and evaluated cost reductions over 1
year. The University of Florida partnered with primary care
professionals across the state to implement PGx as part of routine
patient care. Vanderbilt University Medical Center developed CDS
within adopter sites to select and genotype prospective patients.
From their experience, the following consensus strategy
emerged for PGx implementation: (i) integrate genomic results
into EHRs, and provide CDS; (ii) educate prescribers to effectively
use PGx information; and (iii) engage patients.
With PG4KDS, St. Jude’s successfully implemented preemptive
PGx in over 1000 patients. Key elements of success included a
process to manage return of results and incidental ﬁndings,
extensive use of informatics, development of EHR and CDS, and
broad clinician education efforts.41
The University of Chicago’s 1200 patient project model relied on
a point-of-care informatics support, the genomic prescribing
system (GPS) to bridge: (i) information dissemination and provider
education; (ii) instantaneous availability of results; and (iii) clinical
interpretation and guidance. To demonstrate the acceptance and
feasibility of PGx use in busy clinical settings, ‘early-adopter’
physicians were recruited for the 1200 patient project. At each
patient visit, providers were monitored on their access of the GPS
to query PGx information during treatment decision-making. By
studying early-adopter provider-patient pairs incorporating a
broad range of PGx information, the project hopes to gain
important insights into the PGx implementation processes.42
Despite signiﬁcant progress, reported challenges still need to be
overcome. Currently, there are no standard methods for creating
alerts about actionable variants and each site in the IGNITE
network created their own CDS rules.39
CDS: challenges and solutions
CDS systems can be designed as separate programs, web services,
or mobile applications. CDS systems that are tailored for use
within the local EHR are often restricted to the respective local
health IT infrastructure. Although some genomic data-sharing
standards have been developed, commercial EHR platforms have
been slow to incorporate the standards or to facilitate the ﬂow of
structured information across different systems.
A CDS system developed by The Ubiquitous Pharmacoge-
nomics (U-PGx) Consortium presents a solution for mobilizing PGx
data that also engages patients in their own health care. The U-
PGx Consortium, funded by the European Union, evaluated tools
to integrate PGx test results across health-care institutions in
seven European countries.43 A ﬂexible mobile-based CDS system,
entitled the Medication Safety Code (MSC), was evaluated among
physicians and pharmacists. The MSC system stores PGx data in
Table 3. Comparison of data warehousing and CDS for PGx implementation projects40–42
Site/project Data storage and security CDS
Indiana University—INGenious: INdiana
Genomics Implementation: an Opportunity
for the UnderServed
Data in secured database and Eskanzi
EHR
• Automatic alerts
• Links to guidelines and supporting evidence for patients
with pharmacogenomic results
University of Florida—UF Health Personalized
Medicine Program
Clinical data in EHR; secure facilities • Alert-based informed message that integrates EHR and
allele data
• Includes link to patient education materials
Vanderbilt University—Integrated,
Individualized and Intelligent Prescribing
(I3P) Network
Data stored on individual site servers;
Veterans Affairs site data on FISMA
compliant server
• Passive and active alerts
• Includes interpretative recommendations
• Link to external information sources (e.g.,
MyCancerGenome.org)
St. Jude Children’s Research Hospital—
PG4KDS protocol
Data posted to EHR through in-house
custom web-based applications, DMET
Tracker and Consult Builder
• Active alerts presented for high-risk drugs with
recommendations to guide prescribing
University of Chicago—The 1200 Patients
Project
Clinical data in protected-access web-
portal, the genomic prescribing system
(GPS)
• Patient-speciﬁc drug interpretation as summary
providers can read in <30 s, dynamic feature allows system
use in real time as new treatments considered
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two-dimensional quick response codes to be interpreted by
smartphones and other devices. The MSC system, which is
provided as a personalized pocket card carried by the patient,
was successfully used to alert physicians and pharmacists to PGx
recommendations.44
The International (IFCC) Pharmacogenetics Expertcenter at the
Department of Clinical Chemistry, Erasmus MC, Rotterdam, has
used personalized pocket cards since 2013 to transfer genotype
information to the physician and pharmacist: making the patient
the carrier of their information. Although this approach is limited
in the amount of information that can be mobilized, its use in the
Netherlands has been successful since dosing information per
genotype is already available at every pharmacist through the
DPWG guidelines that are incorporated in a national network.
Educational support for primary care prescribers
Primary care prescribers are, in general, unfamiliar with PGx data.
Educational support for prescribers to feel comfortable using PGx
data to make clinical decisions is vital for the success of any PGx
program. In two surveys conducted in the US, physicians had
reported near-universal acceptance of the concept of PGx, but had
rarely been educated on the topic and felt unprepared for
ordering and using test results.45,46 The response of primary care
physicians to PGx CDS alerts indicated that many did not ﬁnd
them useful.47 More than 50% found the alerts confusing, and had
difﬁculty in locating additional information. Hence only 30% of the
prescribers that received a CDS alert changed their prescription to
an alternative medication. Surveys indicated that 45% of primary
care prescribers were unsure about the use of PGx CDS in the
future.
On the contrary, primary care prescribers in institutional PGx
programs felt adequately supported to use the results in their
clinical practice.48 These prescribers had attended educational
seminars, received informational brochures, and had direct
communications with PGx program leaders. A total 99% of
prescribers agreed that PGx variants inﬂuence patient response to
drug therapy. However, they could not agree on how to assign
clinical responsibility for actionable results, indicating prescribers
do not feel comfortable with genetic information not directly
related to their specialty.
Pharmacists can be assigned clinical responsibility for action-
able PGx results, and can play a key role in helping primary care
prescribers deliver and interpret PGx testing. A pharmacist-led
surveillance team reviewed electronic records of CYP2C19 variant
status for patients who were prescribed clopidogrel following a
coronary stent.49 Pharmacists directly messaged attending physi-
cians using a system built into the EHR. Cardiologists receiving
 
PGx panel and marker selection Data processing and bioinformatics
· The advantages and limitations of different 
technologies need to be assessed based on the goals 
of the PGx test.
· An appropriate number of genetic variants should be 
included in the PGx test for accurate haplotype 
determination.
· PGx users must balance cost, sensitivity, and 
specificity when designing the test, choosing 
biomarkers with clinically validated guidelines suitable 
for the population being tested.
· PGx tests need to be optimized to avoid 
indistinguishable diplotypes by careful selection of 
genetic variants.
· A limited number of markers may perform well in a 
homogeneous population; however, in a 
heterogeneous population the same test will fail to 
capture ethnicity-specific variations, resulting in a high 
false negative rate.
· Computational phasing should be used to distinguish 
haplotype information, unless data is obtained using 
4th generation sequencing technology.
· Development of professional guidelines for 
combinatorial gene testing would improve agreement 
between commercial Decision Support Tools. 
· Establishing the copy number status for CYP2D6 may 
require inclusion of control samples and development 
of independent algorithms to improve accuracy.
noitatnemelpmInoitaterpretni lanoitcnuF
· Standardized terms proposed by the CPIC should be 
used.
· Guidelines for electronic distribution and access to 
PGx results must be adapted to ensure results are 
available when needed; CDS systems should be 
designed to facilitate flow of information across 
various EHRs.
· PGx users need to be aware that minor discrepancies 
exist in PGx reporting/recommendations between CPIC, 
DPWG and FDA.
· CDS alerts must be highly specific, clear, and 
integrated into the workflow to be useful to 
prescribers.
· Uncharacterized alleles should be flagged and 
reported as “unknown functional consequence” and 
clinical interpretation deferred to PGx experts.
· Educational and institutional support should be 
developed to help prescribers use PGx data; 
development of educational outreach to communicate 
the benefits of PGx testing to the patient.
· PGx reports should include references to guidelines 
used for recommendations.
· Establishing PGx clinics with trained pharmacists to 
educate patients about PGx testing, highlight results 
relevant to currently prescribed medications, and 
recommend dosing or drug adjustments to physicians 
has been shown to be a successful model.
Key Considerations
Fig. 3 Summary of key considerations underlying four broad areas of pharmacogenomics: PGx panel and marker selection, data processing
and bioinformatics, functional interpretation, implementation
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direct notiﬁcation of CYP2C19 status for patients with a variant
affecting clopidogrel metabolism suggested alternative medica-
tions. Over a 12-month period, 58% of poor metabolizers and 33%
of intermediate metabolizers received alternatives to clopidogrel,
with CYP2C19 variant status being the most inﬂuential factor
impacting prescribing decisions.
Patient engagement
Personalized medicine is essentially individualized and therefore an
opportunity to engage patients in their own health care. To realize
the anticipated lifetime beneﬁts of PGx, the results will need to be
shared with health-care providers belonging to a patients’ circle of
care. Although PGx has gained considerable recognition, physicians
are still reluctant to adopt PGx into routine practice. Increased
availability of direct-to-consumer PGx testing has led to patients
taking initiative to utilize the beneﬁts of PGx. Pre-emptive
commercial PGx tests can provide value for patients, covering
multiple commonly prescribed medications in anticipation of future
prescription events. However, the ‘burden of disclosure’ often
becomes the patients’ responsibility.50 Strategies to communicate
the beneﬁcial aspects of genomic medicine need to be developed
to fully engage patients as potential drivers of PGx utilization.
CONCLUSION
The expansion of available genomic data has led to a rapid
increase in the number of PGx variants identiﬁed. Efforts to assign
function and determine dosing recommendations for these
variants remains an ongoing effort. Despite signiﬁcant progress
in standardizing different aspects of PGx testing, panels vary in the
pharmacogenomic variants included, affecting test speciﬁcity and
sensitivity, leading to a confusing marketplace with many
apparently similar panels offering different value. A lack of
understanding of the underlying technology of a PGx test often
results in prescribers and other potential users of PGx viewing the
validity of PGx testing with mistrust, rather than as a tool that
leads to better drug outcomes and increases the quality of patient
care. Greater familiarity with key technological aspects can help
potential users gain acceptance of PGx, and facilitate discernment
of which PGx tests better suits their needs. PGx is not an absolute
science, but provides opportunities for informed decision-making;
and PGx results can be used along with other clinical criteria for
prescribing decisions. This approach is exempliﬁed by warfarin-
dosing algorithms that use both genetic and non-genetic factors
to individualize warfarin doses.51 However, more work needs to be
done to overcome barriers to implementation before PGx testing
can become standard-of-care like any other biochemical test
offered by health-care providers (Fig. 3). Efforts continue to bridge
the gap between the science of PGx and real-world application, as
wide-spread implementation moves closer to realization.
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